4 January 2022
CVS Group Plc
("CVS", the "Company" or the "Group")
Exercise of Options, PDMR Dealing and Total Voting Rights
CVS, one of the UK's leading providers of integrated veterinary services, announces that on 4 January 2022, options over a total of 63,320 new ordinary shares of 0.2 pence each (the "New Shares") were exercised under the CVS Group 2018 SAYE Plan (2018/2021), at an exercise price of £8.30.
Richard Fairman, Chief Executive Officer, and Ben Jacklin, Chief Operating Officer, each exercised options over 737 ordinary shares of 0.2p in the Company ("Ordinary Shares"). The balance of the options were exercised by certain other employees and former employees of the Company.
Following their respective option exercises, Richard Fairman holds a beneficial interest in 29,462 Ordinary Shares in the Company, representing approximately 0.042 per cent of the total voting rights of the Company following the issue of the New Shares, and Ben Jacklin holds a beneficial interest in 5,446 Ordinary Shares in the Company, representing approximately 0.008 per cent of the total voting rights of the Company, calculated on the same basis.
Following the issue of the New Shares, the Company has a total issued share capital of 70,934,113 Ordinary Shares each carrying one voting right. The Company holds no Ordinary Shares in treasury. Therefore, following the issue of the New Shares, the total number of voting rights in the Company will be 70,934,113. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
This announcement is released by CVS Group plc and contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"), encompassing information relating to trading for the Company's current financial year, and is disclosed in accordance with the Company's obligations under UK MAR. This announcement is being made on behalf of the Company by the director named below.
Contacts:
| CVS Group plc | via MHP Communications |
| Richard Fairman, CEO |
|
| Jenny Farrer, Company Secretary |
|
| Singer Capital Markets (Nominated Adviser & Broker) | +44 20 7496 3000 |
| Aubrey Powell / Jen Boorer / Rachel Hayes |
|
| MHP Communications (Financial PR) | +44 20 3128 8549 |
| Andrew Jaques / Rachel Mann / Charles Hirst |
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Richard Fairman |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification /Amendment | Initial Notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | CVS Group plc |
| b) | LEI | 213800J41XDQ2NX48O05 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.2 pence each
GB00B2863827 |
| b) | Nature of the transaction | Exercise of options under the 2018 SAYE Plan (1 January 2022 maturity)
|
| c) | Price(s) and volume(s) |
|
| d) | Aggregated information
- Aggregated volume
- Price |
N/A - single transaction |
| e) | Date of the transaction | 4 January 2022 |
| f) | Place of the transaction | London Stock Exchange |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Ben Jacklin | |||
|
|
|
| |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chief Operating Officer | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | CVS Group plc | |||
| b) | LEI | 213800J41XDQ2NX48O05 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.2 pence each
GB00B2863827 | |||
| b) | Nature of the transaction | Exercise of options under the 2018 SAYE Plan (1 January 2022 maturity) | |||
| c) | Price(s) and volume(s) |
| |||
|
| Price(s) | Volume(s) |
| ||
| £8.30 | 737 | ||||
|
|
|
|
|
|
|
|
| |||||
| d) | Aggregated information
- Aggregated volume
- Price |
N/A - single transaction | |||
| e) | Date of the transaction | 4 January 2022 | |||
| f) | Place of the transaction | London Stock Exchange | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
